A5063647700- Acute Myeloid Leukemia Research
- Colorectal Cancer Treatments and Studies
- Gastric Cancer Management and Outcomes
- Erythrocyte Function and Pathophysiology
- Political Influence and Corporate Strategies
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Colorectal Cancer Surgical Treatments
- Cancer Genomics and Diagnostics
- Neuroendocrine Tumor Research Advances
- Colorectal and Anal Carcinomas
- Hepatocellular Carcinoma Treatment and Prognosis
- Lung Cancer Research Studies
- Genetic factors in colorectal cancer
- Lung Cancer Treatments and Mutations
- Local Government Finance and Decentralization
- Neuroblastoma Research and Treatments
- Nonprofit Sector and Volunteering
- Hematopoietic Stem Cell Transplantation
- Multiple Myeloma Research and Treatments
- Fiscal Policies and Political Economy
- Corporate Taxation and Avoidance
- Sleep and related disorders
- Corruption and Economic Development
- Fiscal Policy and Economic Growth
- Colorectal Cancer Screening and Detection
University of British Columbia
2022-2025
BC Cancer Agency
2023-2025
Instituto de Oncologia do Paraná
2022
Organisation de Coopération et de Développement Economiques
2021
Hospital Felício Rocho
2021
Centro de Pesquisas Oncológicas
2021
Universidade Federal do Ceará
2014-2020
Hospital de Clínicas de Porto Alegre
2020
Hospital Universitário Walter Cantídio
2017
<p>Prevalence of CHIP variants across cohorts and association with age. <b>A,</b> Percentage patients in each cohort. Insert shows the breakdown by tumor type PREDiCT-l <b>B,</b> Number a variant gene; <i>DNMT3A</i>, <i>TET2</i>, <i>ASXL1</i>. <b>C,</b> Protein position coding gene. Each lollipop represents patient, multiple dots show same position, red outlines high impact (frameshift or stop gain). Orange bars...
<p>Consort diagram and reasons for exclusion.</p>
<p>CHIP and adverse events. <b>A,</b> Percentage of patients on each treatment that had an event therapy, split by cohort treatment. <b>B,</b> Proportions with events CHIP status. Lighter shades indicate no event, darker event. <i>P</i> values were determined Fisher exact tests.</p>
<p>Progression free survival for patients on PREDiCT-l, split by tumor type. Therapy received is indicated in each title above Kaplan Meier curve.</p>
<p>TRIPOD checklist</p>
<p>CHIP and treatment outcomes. Kaplan–Meier curves showing the difference in outcome between patients with (CHIP+) without CHIP (CHIP−) outcomes on different therapies. PFS is shown left two columns for all three cohorts, OS right CO.26 (top row) PA.7 (middle row). Hazard ratios displayed are derived from univariable Cox proportional hazards models, interaction <i>P</i> values multivariable models (see “Materials Methods”).</p>
<p>VAF of all CHIP variants split by cohort</p>
<div>Abstract<p>Clonal hematopoiesis of indeterminate potential (CHIP) is the clonal expansion hematopoietic stem cells from somatic mutations. It a common incidental finding in cell-free DNA (cfDNA). We investigated incidence CHIP cfDNA patients with solid tumors and explored its association treatment outcomes adverse events. reviewed results local prospective tumor cohort (PREDiCT-l) two randomized trials: Canadian Cancer Trials Group CO.26 [durvalumab + tremelimumab (D T) or...
<p>All CHIP variants identified in the study</p>
<p>Baseline characteristics of the included patients</p>
Multiple Myeloma (MM) is a mature hematological neoplasm characterized by histological infiltration (bone marrow and/or extramedullary plasmacytomas) clonal plasma cells and the presence of one or more defining events, including anemia, renal impairment, osteolytic lesions, hypercalcemia. The management MM has drammaticaly evolved over past few years. However, new drugs are not available in Brazilian public health service treatment still challenge, especially relapsed/refractory setting. We...
275 Background: While detection of MRD using ctDNA is prognostic for recurrence in CRC, some patients still recur prior to detection. VICTORI prospectively investigating NeXT Personal, an ultra-sensitive NGS-based assay, profile with resected CRC. Methods: Patients CRC treated curative intent (all stages) are tested a bespoke assay up ~1,800 tumor-informed single nucleotide variants (SNVs) identified from whole-genome sequencing. Plasma collected surgery, every 2 weeks post-surgery week 8...
Advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) constitute a heterogeneous group of incurable cancers. Lenvatinib is an oral multiple kinase inhibitor that showed activity in grade 1/2 GEP-NENs the phase II TALENT trial, but confirmatory III study has yet to be conducted. To investigate real-world use lenvatinib treating patients with advanced GEP-NENs, we retrospectively analyzed cohort adults unresectable (NENs) from two academic centers Canada who received palliative...
Abstract Purpose: Sidedness is prognostic and predictive of anti-EGFR efficacy in metastatic colorectal cancer (mCRC). Transverse colon has been historically excluded from several analyses sidedness the optimal division between left- right-sided unclear. We investigated transverse primary tumor location as a biomarker mCRC. Experimental Design: Pooled analysis CCTG/AGITG CO.17 CO.20 trials cetuximab chemotherapy-refractory Outcomes patients with RAS/BRAF wild-type (WT) mCRC KRAS WT were...
4098 Background: Advances in systemic therapy for HCC have increased treatment options, including TKIs and immunotherapy combinations. Variables that predict patient outcomes may be helpful personalizing decisions. The aim of this study was to identify predictors short-term death (STD) long-term survival (LTS) patients. Methods: Retrospective review patients with advanced who received a TKI or combinations conducted between Aug 2018 2022 the Canadian provinces British Columbia, Alberta, Nova...
169 Background: Clonal hematopoesis of indeterminate potential (CHIP) is the acquisition somatic mutations leading to clonal expansion hematopoietic stem cells and a common incidental finding in circulating tumor DNA (ctDNA). Inflammation from these or reduced marrow reserve may impact treatment outcomes adverse events. We investigated incidence CHIP ctDNA patients with gastrointestinal (GI) cancers explored its association events (AEs). Methods: collected results local prospective...
4111 Background: Lenvatinib (LEN) and the combination of atezolizumab with bevacizumab (AB) are widely considered first-line systemic therapies for treatment advanced hepatocellular carcinoma (HCC), but have never been compared directly in a randomized clinical trial. Cross-trial comparisons between IMbrave150 LEAP-002 appear to show similar survival outcomes AB LEN, respectively, while LEN was shorter REFLECT Methods: Patients treated or HCC from August 2018 2022 Canadian provinces British...
Abstract Octreotide LAR is a long‐acting somatostatin analogue (SSA) used in the management of metastatic gastroenteropancreatic neuroendocrine tumors (GEP NETs). It requires intramuscular (IM) injection. Missed IM injections cause subcutaneous nodules (SCNs) on radiologic images. We reviewed rates SCNs real‐world cohort GEP NETs receiving octreotide and explored treatment outcomes. Patients commencing between August 5, 2010 March 8, 2018 at single cancer center Canada were identified from...
<p>Supplementary data</p>